BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? Journal of Hepatology 2011;54:1020-9. [DOI: 10.1016/j.jhep.2010.11.007] [Cited by in Crossref: 101] [Cited by in F6Publishing: 99] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Arman T, Lynch KD, Goedken M, Clarke JD. Sub-chronic microcystin-LR renal toxicity in rats fed a high fat/high cholesterol diet. Chemosphere 2021;269:128773. [PMID: 33143886 DOI: 10.1016/j.chemosphere.2020.128773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Clarke JD, Dzierlenga AL, Nelson NR, Li H, Werts S, Goedken MJ, Cherrington NJ. Mechanism of Altered Metformin Distribution in Nonalcoholic Steatohepatitis. Diabetes 2015;64:3305-13. [PMID: 26016715 DOI: 10.2337/db14-1947] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
3 Carter D, Dieterich DT, Chang C. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation. Clin Liver Dis 2018;22:213-27. [PMID: 29128058 DOI: 10.1016/j.cld.2017.08.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
4 Yang Y, Yang X, Lin Y, Yang G, Li L. LASS2 regulates hepatocyte steatosis by interacting with NDUFS2/OXPHOS related proteins. Biochem Biophys Res Commun 2020;526:871-9. [PMID: 32279995 DOI: 10.1016/j.bbrc.2020.02.166] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Akahane T, Akahane M, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, Sawada Y, Shimozato N, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mitoro A, Yoshiji H. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. J Clin Med 2020;9:E1635. [PMID: 32481684 DOI: 10.3390/jcm9061635] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Li Y, Sun X, Yu Y. Serum fetuin-A levels related with microalbuminuria in diet-induced obese rats. Biomed Res Int 2013;2013:795103. [PMID: 23710462 DOI: 10.1155/2013/795103] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
7 Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int. 2013;12:125-135. [PMID: 23558065 DOI: 10.1016/s1499-3872(13)60021-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
8 Chinnadurai R, Ritchie J, Green D, Kalra PA. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease. Nephrology Dialysis Transplantation 2019;34:449-57. [DOI: 10.1093/ndt/gfx381] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
9 Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP. Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. Expert Opin Pharmacother 2012;13:287-8; author reply 289-90. [PMID: 22242725 DOI: 10.1517/14656566.2012.644449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
10 Li Y, Zhu S, Li B, Shao X, Liu X, Liu A, Wu B, Zhang Y, Wang H, Wang X, Deng K, Liu Q, Huang M, Liu H, Holthöfer H, Zou H. Association between non-alcoholic fatty liver disease and chronic kidney disease in population with prediabetes or diabetes. Int Urol Nephrol 2014;46:1785-91. [DOI: 10.1007/s11255-014-0796-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
11 Wong RJ, Kachru N, Martinez DJ, Moynihan M, Ozbay AB, Gordon SC. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases. J Clin Gastroenterol 2021;55:891-902. [PMID: 32815873 DOI: 10.1097/MCG.0000000000001409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
12 Sesti G, Fiorentino TV, Arturi F, Perticone M, Sciacqua A, Perticone F. Association between noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver disease. PLoS One. 2014;9:e88569. [PMID: 24520400 DOI: 10.1371/journal.pone.0088569] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
13 Takahashi S, Tanaka M, Furuhashi M, Moniwa N, Koyama M, Higashiura Y, Osanami A, Gocho Y, Ohnishi H, Numata K, Hisasue T, Hanawa N, Miura T. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep 2021;11:8606. [PMID: 33883636 DOI: 10.1038/s41598-021-88025-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Li X, Xu H, Xiao XC, Deng SL, Wang W, Tang R. Prognostic effect of high-flux hemodialysis in patients with chronic kidney disease. Braz J Med Biol Res 2016;49:e4708. [PMID: 26628394 DOI: 10.1590/1414-431X20154708] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
15 Sharma N, Sircar A, Anders HJ, Gaikwad AB. Crosstalk between kidney and liver in non-alcoholic fatty liver disease: mechanisms and therapeutic approaches. Arch Physiol Biochem 2020;:1-15. [PMID: 32223569 DOI: 10.1080/13813455.2020.1745851] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Han EN, Cheong ES, Lee JI, Kim MC, Byrne CD, Sung KC. Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. Clin Hypertens 2015;21:22. [PMID: 26893932 DOI: 10.1186/s40885-015-0032-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
17 Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol 2014; 20(37): 13306-13324 [PMID: 25309067 DOI: 10.3748/wjg.v20.i37.13306] [Cited by in CrossRef: 118] [Cited by in F6Publishing: 116] [Article Influence: 14.8] [Reference Citation Analysis]
18 Hussein NS, S Helmy A, Sherif NM, Ghanem HZ, A Ibrahim N, El Gendy ANG, Abdel-Hamid AZ. Lipidomic analysis reveals the efficiency of Eclipta prostrata on diet-induced nonalcoholic fatty liver disease in rats. J Pharm Biomed Anal 2019;165:224-32. [PMID: 30553982 DOI: 10.1016/j.jpba.2018.11.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 Mirrakhimov AE. Chronic obstructive pulmonary disease and glucose metabolism: a bitter sweet symphony. Cardiovasc Diabetol 2012;11:132. [PMID: 23101436 DOI: 10.1186/1475-2840-11-132] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 7.0] [Reference Citation Analysis]
20 Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Mori K, Miyamori D, Koyama M, Ohnishi H, Moniwa N, Numata K, Hisasue T, Hanawa N, Miura T. Elevated Fatty Liver Index Is Independently Associated With New Onset of Hypertension During a 10-Year Period in Both Male and Female Subjects. J Am Heart Assoc 2021;10:e021430. [PMID: 34259033 DOI: 10.1161/JAHA.121.021430] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Reference Citation Analysis]
22 Pan L, Zhang H, Huang Z, Sun Q, Chen Z, Li Z, Yang S, Li X, Li X. Intrahepatic triglyceride content is independently associated with chronic kidney disease in obese adults: A cross-sectional study. Metabolism 2015;64:1077-85. [DOI: 10.1016/j.metabol.2015.06.003] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
23 Di Sessa A, Guarino S, Melone R, De Simone RF, Marzuillo P, Miraglia del Giudice E. Relationship between nonalcoholic fatty liver disease and chronic kidney disease could start in childhood. World J Gastroenterol 2021; 27(34): 5793-5795 [PMID: 34629802 DOI: 10.3748/wjg.v27.i34.5793] [Reference Citation Analysis]
24 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
25 Hawksworth DJ, Burnett AL. Nonalcoholic Fatty Liver Disease, Male Sexual Dysfunction, and Infertility: Common Links, Common Problems. Sexual Medicine Reviews 2020;8:274-85. [DOI: 10.1016/j.sxmr.2019.01.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Li G, Shi W, Hug H, Chen Y, Liu L, Yin D. Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population. Biochem Med (Zagreb). 2012;22:92-99. [PMID: 22384523 DOI: 10.11613/bm.2012.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
27 VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15:75-85. [PMID: 27218012 DOI: 10.1007/s11901-016-0295-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 9.5] [Reference Citation Analysis]
28 Vilar-Gomez E, Calzadilla-Bertot L, Friedman SL, Gra-Oramas B, Gonzalez-Fabian L, Villa-Jimenez O, Lazo-Del Vallin S, Diago M, Adams LA, Romero-Gomez M, Chalasani N. Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2017;45:332-344. [PMID: 27862096 DOI: 10.1111/apt.13860] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
29 Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence? J Hepatol. 2018;68:335-352. [PMID: 29122390 DOI: 10.1016/j.jhep.2017.09.021] [Cited by in Crossref: 224] [Cited by in F6Publishing: 212] [Article Influence: 44.8] [Reference Citation Analysis]
30 Bellinato F, Goio I, Malara G, Rosato A, Targher G, Girolomoni G, Gisondi P. Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis. J Cutan Med Surg 2021;:12034754211066906. [PMID: 34894782 DOI: 10.1177/12034754211066906] [Reference Citation Analysis]
31 Li Y, Liu L, Wang B, Xiong J, Li Q, Wang J, Chen D. Impairment of reproductive function in a male rat model of non-alcoholic fatty liver disease and beneficial effect of N-3 fatty acid supplementation. Toxicology Letters 2013;222:224-32. [DOI: 10.1016/j.toxlet.2013.05.644] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
32 Shah RV, Allison MA, Lima JA, Abbasi SA, Mongraw-Chaffin M, Jerosch-Herold M, Ding J, Budoff MJ, Murthy VL. Liver steatosis and the risk of albuminuria: the multi-ethnic study of atherosclerosis. J Nephrol 2015;28:577-84. [PMID: 25712234 DOI: 10.1007/s40620-015-0177-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138-1153. [PMID: 28314735 DOI: 10.1136/gutjnl-2017-313884] [Cited by in Crossref: 384] [Cited by in F6Publishing: 366] [Article Influence: 76.8] [Reference Citation Analysis]
34 Zhan YT, Zhang C, Li L, Bi CS, Song X, Zhang ST. Non-alcoholic fatty liver disease is not related to the incidence of diabetic nephropathy in Type 2 Diabetes. Int J Mol Sci 2012;13:14698-706. [PMID: 23203089 DOI: 10.3390/ijms131114698] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
35 Hussain SM, Sureshkumar KK. Refining the Role of Simultaneous Liver Kidney Transplantation. J Clin Transl Hepatol. 2018;6:289-295. [PMID: 30271741 DOI: 10.14218/jcth.2017.00065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
36 Umbro I, Tinti F, Scalera I, Evison F, Gunson B, Sharif A, Ferguson J, Muiesan P, Mitterhofer AP. Acute kidney injury and post-reperfusion syndrome in liver transplantation. World J Gastroenterol 2016; 22(42): 9314-9323 [PMID: 27895419 DOI: 10.3748/wjg.v22.i42.9314] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
37 Pallayova M, Taheri S. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. Clin Obes. 2014;4:243-253. [PMID: 25825857 DOI: 10.1111/cob.12068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
38 Paik J, Golabi P, Younoszai Z, Mishra A, Trimble G, Younossi ZM, Negro F. Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease. Liver Int 2019;39:342-52. [DOI: 10.1111/liv.13992] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
39 Giorda CB, Forlani G, Manti R, Mazzotti A, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P, Tartaglino B, Russo G; AMD-Annals Study Group. Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients. Diabetes Res Clin Pract 2018;135:65-72. [PMID: 29097288 DOI: 10.1016/j.diabres.2017.10.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
40 Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res 2016;2016:2931985. [PMID: 27123461 DOI: 10.1155/2016/2931985] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
41 Xu JY, Li ZP, Zhang L, Ji G. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(37): 13493-13500 [PMID: 25309079 DOI: 10.3748/wjg.v20.i37.13493] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
42 Jang HR, Kang D, Sinn DH, Gu S, Cho SJ, Lee JE, Huh W, Paik SW, Ryu S, Chang Y, Shafi T, Lazo M, Guallar E, Cho J, Gwak GY. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Sci Rep. 2018;8:4718. [PMID: 29549269 DOI: 10.1038/s41598-018-23014-0] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 8.5] [Reference Citation Analysis]
43 Zubair R, Mirza M, Iftikhar J, Saeed N. Frequency of incidental fatty liver on ultrasound and its association with diabetes mellitus and hypertension. Pak J Med Sci 2018;34:1137-41. [PMID: 30344564 DOI: 10.12669/pjms.345.15102] [Reference Citation Analysis]
44 Hörist-kollmann S, Strametz-juranek J. Female Dietary Patterns and the Pathogenesis of NAFLD. Gender and the Genome 2018;2:49-55. [DOI: 10.1177/2470289718787091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
45 Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients. Journal of Clinical Gastroenterology 2018;52:268-72. [DOI: 10.1097/mcg.0000000000000905] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
46 Xu H, Hsu Y, Chang C, Wei K, Lin C. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatol Int 2016;10:340-6. [DOI: 10.1007/s12072-015-9690-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
47 Chondronikola M, Sarkar S. Total-body PET Imaging: A New Frontier for the Assessment of Metabolic Disease and Obesity. PET Clin 2021;16:75-87. [PMID: 33160928 DOI: 10.1016/j.cpet.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Machado MV, Gonçalves S, Carepa F, Coutinho J, Costa A, Cortez-pinto H. Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease. Liver Int 2012;32:241-8. [DOI: 10.1111/j.1478-3231.2011.02623.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
49 Giorda CB, Picariello R, Tartaglino B, Nada E, Linzalata C, Romeo F, Costa G, Gnavi R. Hepatic fibrosis of any origin in a large population of type 2 diabetes patients. Nutr Metab Cardiovasc Dis 2021:S0939-4753(21)00316-1. [PMID: 34364773 DOI: 10.1016/j.numecd.2021.06.020] [Reference Citation Analysis]
50 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 95.7] [Reference Citation Analysis]
51 Sung K, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. Journal of Hepatology 2014;60:1040-5. [DOI: 10.1016/j.jhep.2014.01.009] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 10.4] [Reference Citation Analysis]
52 Bulum T, Kolarić B, Duvnjak M, Duvnjak L. Alkaline phosphatase is independently associated with renal function in normoalbuminuric type 1 diabetic patients. Ren Fail 2014;36:372-7. [PMID: 24455970 DOI: 10.3109/0886022X.2013.872569] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
53 Mikolasevic I, Milic S, Turk Wensveen T, Grgic I, Jakopcic I, Stimac D, Wensveen F, Orlic L. Nonalcoholic fatty liver disease - A multisystem disease? World J Gastroenterol 2016; 22(43): 9488-9505 [PMID: 27920470 DOI: 10.3748/wjg.v22.i43.9488] [Cited by in CrossRef: 91] [Cited by in F6Publishing: 85] [Article Influence: 15.2] [Reference Citation Analysis]
54 Williams KH, Shackel NA, Gorrell MD, McLennan SV, Twigg SM. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev. 2013;34:84-129. [PMID: 23238855 DOI: 10.1210/er.2012-1009] [Cited by in Crossref: 132] [Cited by in F6Publishing: 127] [Article Influence: 13.2] [Reference Citation Analysis]
55 Clarke JD, Cherrington NJ. Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability. Pharmacol Ther 2015;151:99-106. [PMID: 25805597 DOI: 10.1016/j.pharmthera.2015.03.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
56 Caragata R, Wyssusek KH, Kruger P. Acute kidney injury following liver transplantation: a systematic review of published predictive models. Anaesth Intensive Care 2016;44:251-61. [PMID: 27029658 DOI: 10.1177/0310057X1604400212] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
57 Hsieh MH, Wu KT, Chen YY, Yang JF, Lin WY, Chang NC, Lin CY, Huang CK, Wang CL, Chuang HY, Lin SC, Hsu YK, Tsai YS, Chuang WL, Yu ML, Dai CY. Higher NAFLD fibrosis score is associated with impaired eGFR. J Formos Med Assoc. 2020;119:496-503. [PMID: 31353118 DOI: 10.1016/j.jfma.2019.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
58 Heidari Z, Gharebaghi A. Prevalence of Non Alcoholic Fatty Liver Disease and its Association with Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus. J Clin Diagn Res 2017;11:OC04-7. [PMID: 28658824 DOI: 10.7860/JCDR/2017/25931.9823] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
59 Wijarnpreecha K, Aby ES, Ahmed A, Kim D. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021;27:221-35. [PMID: 33317243 DOI: 10.3350/cmh.2020.0239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
60 Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol 2015; 21(22): 6820-6834 [PMID: 26078558 DOI: 10.3748/wjg.v21.i22.6820] [Cited by in CrossRef: 88] [Cited by in F6Publishing: 80] [Article Influence: 12.6] [Reference Citation Analysis]
61 Mikolasevic I, Racki S, Zaputovic L, Lukenda V, Milic S, Orlic L. Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients. Med Hypotheses 2014;82:205-8. [PMID: 24365277 DOI: 10.1016/j.mehy.2013.11.039] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
62 Alhasson F, Dattaroy D, Das S, Chandrashekaran V, Seth RK, Schnellmann RG, Chatterjee S. NKT cell modulates NAFLD potentiation of metabolic oxidative stress-induced mesangial cell activation and proximal tubular toxicity. Am J Physiol Renal Physiol 2016;310:F85-F101. [PMID: 26447219 DOI: 10.1152/ajprenal.00243.2015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
63 Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol. 2012;9:372-381. [PMID: 22565095 DOI: 10.1038/nrgastro.2012.79] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
64 Tarantino G, Citro V, Balsano C. Liver-spleen axis in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2021;15:759-69. [PMID: 33878988 DOI: 10.1080/17474124.2021.1914587] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Hilmi IA, Damian D, Al-Khafaji A, Planinsic R, Boucek C, Sakai T, Chang CC, Kellum JA. Acute kidney injury following orthotopic liver transplantation: incidence, risk factors, and effects on patient and graft outcomes. Br J Anaesth. 2015;114:919-926. [PMID: 25673576 DOI: 10.1093/bja/aeu556] [Cited by in Crossref: 143] [Cited by in F6Publishing: 119] [Article Influence: 20.4] [Reference Citation Analysis]
66 An JN, Joo SK, Koo BK, Kim JH, Oh S, Kim W. Portal inflammation predicts renal dysfunction in patients with nonalcoholic fatty liver disease. Hepatol Int 2020;14:798-807. [DOI: 10.1007/s12072-020-10063-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
67 Alhasson F, Seth RK, Sarkar S, Kimono DA, Albadrani MS, Dattaroy D, Chandrashekaran V, Scott GI, Raychoudhury S, Nagarkatti M, Nagarkatti P, Diehl AM, Chatterjee S. High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease. Redox Biol 2018;17:1-15. [PMID: 29660503 DOI: 10.1016/j.redox.2018.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
68 Jablonski KL, Jovanovich A, Holmen J, Targher G, McFann K, Kendrick J, Chonchol M. Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2013;23:792-798. [PMID: 23415456 DOI: 10.1016/j.numecd.2012.12.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
69 Di Sessa A, Guarino S, Passaro AP, Liguori L, Umano GR, Cirillo G, Miraglia Del Giudice E, Marzuillo P. NAFLD and renal function in children: is there a genetic link?Expert Rev Gastroenterol Hepatol. 2021;1-10. [PMID: 33851883 DOI: 10.1080/17474124.2021.1906649] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Choe AR, Ryu DR, Kim HY, Lee HA, Lim J, Kim JS, Lee JK, Kim TH, Yoo K. Noninvasive indices for predicting nonalcoholic fatty liver disease in patients with chronic kidney disease. BMC Nephrol 2020;21:50. [PMID: 32066395 DOI: 10.1186/s12882-020-01718-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Mikolasevic I, Racki S, Lukenda V, Pavletic-persic M, Milic S, Orlic L. Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction. Medical Hypotheses 2014;82:36-9. [DOI: 10.1016/j.mehy.2013.10.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
72 Li X, Xia M, Ma H, Hu Y, Yan H, He W, Lin H, Zhao NQ, Gao J, Gao X. Liver fat content is independently associated with microalbuminuria in a normotensive, euglycaemic Chinese population: a community-based, cross-sectional study. BMJ Open 2021;11:e044237. [PMID: 34187816 DOI: 10.1136/bmjopen-2020-044237] [Reference Citation Analysis]
73 Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One. 2014;9:e88371. [PMID: 24505484 DOI: 10.1371/journal.pone.0088371] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
74 Huh JH, Kim JY, Choi E, Kim JS, Chang Y, Sung KC. The fatty liver index as a predictor of incident chronic kidney disease in a 10-year prospective cohort study. PLoS One. 2017;12:e0180951. [PMID: 28738057 DOI: 10.1371/journal.pone.0180951] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
75 Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Fallon MB, Biggins SW, Subramanian RM, Thuluvath PJ, Kamath PS, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj JS. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. Am J Gastroenterol 2017;112:1103-10. [PMID: 28440305 DOI: 10.1038/ajg.2017.122] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
76 Liu HW, Liu JS, Kuo KL. Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan. Ci Ji Yi Xue Za Zhi 2020;32:65-9. [PMID: 32110523 DOI: 10.4103/tcmj.tcmj_233_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
77 Houlihan DD, Armstrong MJ, Davidov Y, Hodson J, Nightingale P, Rowe IA, Paris S, Gunson BK, Bramhall SB, Mutimer DJ, Neuberger JM, Newsome PN. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens? Liver Transpl. 2011;17:1292-1298. [PMID: 21761549 DOI: 10.1002/lt.22382] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
78 Targher G, Chonchol M, Pichiri I, Zoppini G. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence? J Endocrinol Invest 2011;34:544-51. [PMID: 21427524 DOI: 10.3275/7614] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
79 Targher G, Chonchol MB, Byrne CD. CKD and nonalcoholic fatty liver disease. Am J Kidney Dis. 2014;64:638-652. [PMID: 25085644 DOI: 10.1053/j.ajkd.2014.05.019] [Cited by in Crossref: 104] [Cited by in F6Publishing: 96] [Article Influence: 13.0] [Reference Citation Analysis]
80 Onat A, Can G, Kaya A, Akbaş T, Özpamuk-Karadeniz F, Şimşek B, Çakır H, Yüksel H. Fatty liver disease: Disparate predictive ability for cardiometabolic risk and all-cause mortality. World J Gastroenterol 2015; 21(48): 13555-13565 [PMID: 26730168 DOI: 10.3748/wjg.v21.i48.13555] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
81 Targher G, Scorletti E, Mantovani A, Byrne CD. Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. Metab Syndr Relat Disord. 2013;11:217-228. [PMID: 23745619 DOI: 10.1089/met.2013.0044] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
82 Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47-S64. [PMID: 25920090 DOI: 10.1016/j.jhep.2014.12.012] [Cited by in Crossref: 1011] [Cited by in F6Publishing: 958] [Article Influence: 168.5] [Reference Citation Analysis]
83 Ahn AL, Choi JK, Kim MN, Kim SA, Oh EJ, Kweon HJ, Cho DY. Non-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Koreans Aged 50 Years or Older. Korean J Fam Med. 2013;34:199-205. [PMID: 23730487 DOI: 10.4082/kjfm.2013.34.3.199] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
84 Kotoku K, Michishita R, Matsuda T, Kawakami S, Morito N, Uehara Y, Higaki Y. The Association between Decreased Kidney Function and FIB-4 Index Value, as Indirect Liver Fibrosis Indicator, in Middle-Aged and Older Subjects. Int J Environ Res Public Health 2021;18:6980. [PMID: 34209974 DOI: 10.3390/ijerph18136980] [Reference Citation Analysis]
85 Shen Z, Munker S, Luo F, Ma H, Yu C, Li Y. Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age. PLoS One 2015;10:e0130614. [PMID: 26087253 DOI: 10.1371/journal.pone.0130614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
86 Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S. Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract 2014;2014:847539. [PMID: 24729784 DOI: 10.1155/2014/847539] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
87 Leite NC, Villela-Nogueira CA, Cardoso CRL, Salles GF. Non-alcoholic fatty liver disease and diabetes: From physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014; 20(26): 8377-8392 [PMID: 25024596 DOI: 10.3748/wjg.v20.i26.8377] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
88 Syed T, Chadha N, Kumar D, Gupta G, Sterling RK. Non-Invasive Assessment of Liver Fibrosis and Steatosis in End-Stage Renal Disease Patients Undergoing Renal Transplant Evaluation. Gastroenterology Res 2021;14:244-51. [PMID: 34527094 DOI: 10.14740/gr1445] [Reference Citation Analysis]
89 Wong F, Reddy KR, O’leary JG, Tandon P, Biggins SW, Garcia‐tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transpl 2019;25:870-80. [DOI: 10.1002/lt.25454] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
90 Dietrich CG, Rau M, Jahn D, Geier A. Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease. Expert Opin Drug Metab Toxicol 2017;13:625-40. [PMID: 28359183 DOI: 10.1080/17425255.2017.1314461] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
91 Minakuchi H, Wakino S, Hosoya K, Sueyasu K, Hasegawa K, Shinozuka K, Yoshifuji A, Futatsugi K, Komatsu M, Kanda T, Tokuyama H, Hayashi K, Itoh H. The role of adipose tissue asymmetric dimethylarginine/dimethylarginine dimethylaminohydrolase pathway in adipose tissue phenotype and metabolic abnormalities in subtotally nephrectomized rats. Nephrol Dial Transplant 2016;31:413-23. [DOI: 10.1093/ndt/gfv367] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
92 Ko SH, Baeg MK, Han KD, Ko SY, Shin SB, Ko SH, Ahn YB. Association between gamma-glutamyltransferase and albuminuria in nondiabetic adults with normal renal function. Clin Exp Nephrol 2017;21:835-41. [PMID: 27933415 DOI: 10.1007/s10157-016-1356-7] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
93 Qin T, Wang M, Zhang T, Wang Y, Zhang Y, Hasnat M, Zhuang Z, Ding Y, Peng Y. Total C-21 Steroidal Glycosides From Baishouwu Ameliorate Hepatic and Renal Fibrosis by Regulating IL-1β/MyD88 Inflammation Signaling. Front Pharmacol 2021;12:775730. [PMID: 34764877 DOI: 10.3389/fphar.2021.775730] [Reference Citation Analysis]
94 Orlic L, Mikolasevic I, Lukenda V, Anic K, Jelic I, Racki S. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr 2015;127:355-62. [DOI: 10.1007/s00508-014-0661-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
95 Kim SG, Kim BK, Kim K, Fang S. Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2016;31:500-4. [PMID: 28029021 DOI: 10.3803/EnM.2016.31.4.500] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
96 Mohamed Ahmed A, Abdel Ghany M, Abdel Hakeem GL, Kamal A, Khattab R, Abdalla A, Abou El Fotoh Lel M, El Mazary AA, Sayed MA, Abdel Fadil AM. Assessment of Vitamin D status in a group of Egyptian children with non alcoholic fatty liver disease (multicenter study). Nutr Metab (Lond) 2016;13:53. [PMID: 27547235 DOI: 10.1186/s12986-016-0112-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
97 Ma YH. Renal dysfunction in patients with nonalcoholic fatty liver disease and risk factors. Shijie Huaren Xiaohua Zazhi 2018; 26(11): 667-672 [DOI: 10.11569/wcjd.v26.i11.667] [Reference Citation Analysis]
98 Lin L, Lu J, Huang X, Ding L, Huang Y, Wang P, Peng K, Zhang D, Xu Y, Xu M, Chen Y, Bi Y, Wang W, Xu Y. Nonalcoholic fatty liver disease is associated with low-grade albuminuria in Chinese adults (change not displayed). QJM 2016;109:737-43. [DOI: 10.1093/qjmed/hcw070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
99 Tasneem AA, Luck NH, Majid Z. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Trop Doct 2018;48:107-12. [PMID: 29145775 DOI: 10.1177/0049475517742261] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
100 Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. Am J Nephrol. 2012;36:466-471. [PMID: 23128368 DOI: 10.1159/000343885] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
101 Khan RS, Newsome PN. Non-alcoholic fatty liver disease and liver transplantation. Metabolism. 2016;65:1208-1223. [PMID: 26997540 DOI: 10.1016/j.metabol.2016.02.013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
102 Villeret F, Dumortier J, Erard-Poinsot D. How will NAFLD change the liver transplant landscape in the 2020s? Clin Res Hepatol Gastroenterol 2021;:101759. [PMID: 34311133 DOI: 10.1016/j.clinre.2021.101759] [Reference Citation Analysis]
103 Clarke JD, Dzierlenga A, Arman T, Toth E, Li H, Lynch KD, Tian DD, Goedken M, Paine MF, Cherrington N. Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. Toxicon 2019;162:1-8. [PMID: 30849452 DOI: 10.1016/j.toxicon.2019.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
104 Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7:796-805. [PMID: 22291824 DOI: 10.5114/aoms.2011.25554] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 3.9] [Reference Citation Analysis]
105 Targher G, Pichiri I, Zoppini G, Trombetta M, Bonora E. Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. Diabet Med. 2012;29:220-226. [PMID: 21883436 DOI: 10.1111/j.1464-5491.2011.03427.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 4.3] [Reference Citation Analysis]